- Trials with a EudraCT protocol (1,312)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,312 result(s) found for: Pathology.
Displaying page 1 of 66.
| EudraCT Number: 2014-000219-15 | Sponsor Protocol Number: 13-10 | Start Date*: 2014-11-27 |
| Sponsor Name:VU Medical Center | ||
| Full Title: Amyloid pathology in cognitively normal elderly subjects | ||
| Medical condition: Cognitively healthy elderly, aged 60-100 years old. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003499-18 | Sponsor Protocol Number: PI2022_843_0111 | Start Date*: 2023-03-22 |
| Sponsor Name:CHU Amiens-Picardie | ||
| Full Title: Is there a concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology to determine the microscopic inflammation at the ileal resection margins in Crohn’s ileal... | ||
| Medical condition: Crohn’s ileal disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-020724-21 | Sponsor Protocol Number: ADR16SUS2 | Start Date*: 2011-04-06 |
| Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien | ||
| Full Title: Amyloid Imaging with [11C]PIB PET and MRI in MCI – a pilot study | ||
| Medical condition: Patients with Mild Cognitive Impairment (MCI) will be investigated with PIB PET to determin amyloid pathology | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002511-22 | Sponsor Protocol Number: 20-05 | Start Date*: 2023-06-08 |
| Sponsor Name:Amsterdam UMC VUmc | ||
| Full Title: Synaptic density and tau pathology in Alzheimer's disease | ||
| Medical condition: Amyloid-beta positive individuals across the Alzheimer's disease continuum | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004192-12 | Sponsor Protocol Number: NL66079.029.18 | Start Date*: 2019-08-05 |
| Sponsor Name:Amsterdam UMC, location VU medical Center | ||
| Full Title: Oil- based versus water-based contrast media for hysterosalpingography (HSG) in infertile women with unevaluated indications: a randomized controlled trial | ||
| Medical condition: The research population consists of infertile couples who have tried to conceive for at least 12 months, or have oligo- or anovulation. We will focus on women with ovulation disorders, or at high r... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-002873-21 | Sponsor Protocol Number: RES100769 | Start Date*: 2005-03-23 |
| Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
| Full Title: A study to assess disease pathology and key therapeutic targets in severe asthma | ||
| Medical condition: Mild to severe persistent asthma. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003007-35 | Sponsor Protocol Number: R2810-ONC-1901 | Start Date*: 2020-02-04 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | |||||||||||||
| Medical condition: Stage II to IV cutaneous squamous cell carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-010861-21 | Sponsor Protocol Number: PRIMOVIST/2009 | Start Date*: 2009-04-24 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
| Full Title: Evaluation of the bilo-enteric anastomoses with contrast-enhanced MR-cholangiopancreatography (MRCP) with PRIMOVIST (Gd-EOB-DTPA-enhanced MRCP): comparison with conventional T2-weighted MRCP. | |||||||||||||
| Medical condition: Patients with clinical-echographical suspect of biliary pathology and pre-existing bilo-enteric anastomoses. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004153-24 | Sponsor Protocol Number: NL62838.029.18 | Start Date*: 2019-07-30 |
| Sponsor Name:Amsterdam UMC - location Vrije Universiteit Amsterdam | ||
| Full Title: Tubal flushing with oil-based contrast during HSG in subfertile women: Is early flushing effective and cost-effective as compared to delayed flushing? | ||
| Medical condition: The research population consists of infertile women aged between 18 and 39 years of age, who have a spontaneous menstrual cycle and with a perceived low risk for tubal pathology, undergoing fertili... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003699-38 | Sponsor Protocol Number: CEDM-MRI | Start Date*: 2021-04-28 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
| Full Title: DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOSYNTHESIS COMPARED TO MR IMAGING WITH GADOLINIUM IN DYNAMI... | |||||||||||||
| Medical condition: Breast souspicious lesions | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001584-23 | Sponsor Protocol Number: 7605 | Start Date*: 2018-10-30 |
| Sponsor Name:University Hospital of Montpellier | ||
| Full Title: "Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714" | ||
| Medical condition: To study in vivo microglial activation by PET [18F] DPA-714 in NT1 patients with recent evolution (appearance of the first symptoms - somnolence and cataplexy-less than 2 years ago) compared with c... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-002966-39 | Sponsor Protocol Number: STH13844 | Start Date*: 2006-12-22 |
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||
| Full Title: A Double-blind randomised controlled trial to compare buscopan versus placebo as an adjunct to colonoscopy | ||
| Medical condition: pathology of the large bowel as detected by colonoscopy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000175-17 | Sponsor Protocol Number: 1100.1448 | Start Date*: 2005-05-31 |
| Sponsor Name: [...] | ||
| Full Title: A pharmacokinetic study to assess Nevirapine levels in HIV-infected patients with impaired hepatic function. | ||
| Medical condition: Treatment of HIV infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-005553-39 | Sponsor Protocol Number: 1501 | Start Date*: 2015-12-29 |
| Sponsor Name:Karolinska University Hospital | ||
| Full Title: Effects of Sativex on blood leukocytes in patients with lymphoma/chronic lymphocytic leukaemia | ||
| Medical condition: Lymphoma and chronic lymphocytic leukaemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000151-40 | Sponsor Protocol Number: SGM-CLIN03 | Start Date*: 2019-06-13 | ||||||||||||||||||||||||||
| Sponsor Name:Surgimab | ||||||||||||||||||||||||||||
| Full Title: Multicenter, semi-blinded, randomized, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for t... | ||||||||||||||||||||||||||||
| Medical condition: Patients undergoing curative surgery for colorectal cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NL (Ongoing) IT (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2018-004255-20 | Sponsor Protocol Number: CHDR1848___OTL-2016-OTL38-006 | Start Date*: 2019-02-26 | |||||||||||
| Sponsor Name:On Target Laboratories, LLC | |||||||||||||
| Full Title: A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer | |||||||||||||
| Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-000636-40 | Sponsor Protocol Number: PNOC022 | Start Date*: 2022-10-20 | |||||||||||||||||||||
| Sponsor Name:Pacific Pediatric Neuro-Oncology Consortium (PNOC) | |||||||||||||||||||||||
| Full Title: PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initi... | |||||||||||||||||||||||
| Medical condition: Diffuse Midline Gliomas, H3K27M mutant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2010-018311-15 | Sponsor Protocol Number: GE-148-003 | Start Date*: 2010-05-21 |
| Sponsor Name:GE Healthcare Limited | ||
| Full Title: A Phase 2, Open-label Study to Assess the Uptake and Retention and Safety of GE 148 (18F) Injection in Subjects with Biopsy-proven Prostate Cancer who are Scheduled for Radical Prostatectomy | ||
| Medical condition: Detection of abnormal amino acid transport using Positron Emission Tomography (PET) in malignancy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000108-27 | Sponsor Protocol Number: H8A-MC-LZBE | Start Date*: 2016-08-25 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease | |||||||||||||
| Medical condition: Prodromal Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004860-78 | Sponsor Protocol Number: P1209NY | Start Date*: 2014-05-09 | |||||||||||
| Sponsor Name:G. Pohl-Boskamp GmbH & Co. KG | |||||||||||||
| Full Title: A randomised, active-controlled, observer-blind, non-inferiority study to investigate the efficacy, safety and tolerability of a local treatment with dimeticone-based pediculicides in head lice inf... | |||||||||||||
| Medical condition: Pediculosis capitis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
